1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition 26
3.2 Scope Of Study 26
3.3 List Of Assumptions 26
3.4 Market Structure 27
4 Research Methodology
4.1 Research Process 29
4.2 Primary Research 30
4.3 Secondary Research 31
4.4 Market Size Estimation 32
4.5 Forecast Model 32
5 Market Dynamics
5.1 Introduction 34
5.2 Drivers 35
5.2.1 Increasing Preference For Minimally Invasive Procedures 35
5.2.2 Rising Prevalence Of Chronic Disorders 36
5.2.3 Improvement In Reimbursement Scenario 37
5.2.4 Rising Geriatric Population 38
5.3 Restraints 39
5.3.1 Rising Treatment Cost And Hospital Stay 39
5.3.2 Lack Of Skilled Physicians 40
5.4 Opportunities 41
5.4.1 New Advancements In Catheterization Devices 41
5.4.2 Guide Wire Assisted Surgery In Elderly Population 41
5.1 Mega Trends 41
5.1.1 Telemedicine 41
5.2 Macroeconomic Indicators 41
5.3 Technology Trends & Assessment 42
6 Market Factor Analysis
6.1 Porterโs Five Forces Model 44
6.1.1 Threat Of New Entrants 44
6.1.2 Bargaining Power Of Suppliers 44
6.1.3 Threat Of Substitutes 45
6.1.4 Bargaining Power Of Buyers 45
6.1.5 Intensity Of Rivalry 45
6.2 Supply Chain Analysis 46
6.2.1 Research &Development 46
6.2.2 Manufacturing 46
6.2.3 Distribution 46
6.2.4 Marketing & Sales 47
6.2.5 Post-Sales Monitoring 47
6.3 Demand & Supply: Gap Analysis 47
6.4 Pricing Analysis 47
6.5 Investment Feasibility Analysis 47
7 Global Transient Ischemic Attack Market, By Diagnosis
7.1 Introduction 49
7.2 Imaging Techniques 49
7.2.1 Computed Tomography (CT) Scan 51
7.2.2 Carotid Duplex Scanning 51
7.2.3 Magnetic Resonance Imaging 52
7.2.4 Echocardiography 52
8 Global Transient Ischemic Attack Market, By Treatment
8.1 Introduction 54
8.2 Surgery 54
8.3 Drugs 54
8.3.1 Surgery 55
8.3.2 Drugs 56
8.3.2.1 Antithrombotic Agents 56
8.3.2.2 Antiplatelets 56
8.3.2.3 Clopidogrel 57
8.3.2.4 Aspirin 57
8.3.2.5 Heparins 57
8.3.2.6 ENOXAPARIN 58
8.3.2.7 DALTEPARIN 58
8.3.2.8 Fibrinolytics 58
8.3.2.9 Tenecteplase 59
8.3.2.10 Alteplase 59
8.3.2.11 Antihypertensive Agents 59
8.3.2.12 Prazosin 60
8.3.2.13 Moxonidine 60
9 Global Transient Ischemic Attack Market, By Age Groups
9.1 Introduction 62
9.2 0โ18 Years 62
9.3 19โ40 Years (Millennial) 62
9.4 41โ60 Years 62
9.5 60+ Years 63
9.5.1 0-18 Years 64
9.5.2 19-40 Years 65
9.5.3 41-60 Years 65
9.5.4 60+ Years 65
10 Global Transient Ischemic Attack Market, By End-User
10.1 Introduction 67
10.2 Hospitals & Clinics 67
10.3 Diagnostic Centers 67
10.4 Research Laboratories 68
10.4.1 Hospitals 69
10.4.2 Diagnostic Centers 70
10.4.3 Research Laboratories 70
11 Global Transient Ischemic Attack Market, By Region
11.1 Introduction 72
11.2 Americas 73
11.2.1 North America 78
11.2.1.1 U.S. 82
11.2.1.2 Canada 86
11.2.2 South America 90
11.3 Europe 94
11.3.1 Western Europe 99
11.3.1.1 Germany 103
11.3.1.2 France 107
11.3.1.3 U.K. 111
11.3.1.4 Italy 115
11.3.1.5 Spain 119
11.3.1.6 Rest Of Western Europe 123
11.3.2 Eastern Europe 127
11.4 Asia Pacific 131
11.4.1 Asia Pacific 132
11.4.2 Japan 136
11.4.3 China 140
11.4.4 India 144
11.4.5 Australia 148
11.4.6 Republic Of Korea 152
11.4.7 Rest Of Asia Pacific 156
11.5 The Middle East & Africa 160
11.5.1 Middle East And Africa 161
11.5.2 United Arab Emirates 164
11.5.3 Saudi Arabia 168
11.5.4 Rest Of Middle East & Africa 172
12 Competitive Landscape
12.1 Company Market Share Analysis 177
12.1.1 Introduction 177
12.2 Company Share Analysis 178
12.3 Recent Developments, 2013โ2018 179
13 Company Profiles
13.1 Koninklijke Philips N.V. 184
13.1.1 Company Overview 184
13.1.2 Financial Overview 184
13.1.3 Products Offering 185
13.1.4 Key Developments 185
13.1.5 SWOT Analysis 185
13.1.6 Key Strategy 186
13.2 Stryker Corporation 187
13.2.1 Company Overview 187
13.2.2 Financial Overview 187
13.2.3 Products Offering 188
13.2.4 Key Developments 188
13.2.5 SWOT Analysis 189
13.2.6 Key Strategy 189
13.3 Johnson & Johnson Services Inc. 190
13.3.1 Company Overview 190
13.3.2 Financial Overview 190
13.3.3 Products Offering 191
13.3.4 Key Developments 191
13.3.5 SWOT Analysis 192
13.3.6 Key Strategy 192
13.4 Boston Scientific Corporation 193
13.4.1 Company Overview 193
13.4.2 Financial Overview 193
13.4.3 Products Offering 194
13.4.4 Key Developments 195
13.4.5 SWOT Analysis 195
13.4.6 Key Strategy 195
13.5 Sanofi 196
13.5.1 Company Overview 196
13.5.2 Financial Overview 196
13.5.3 Products Offering 197
13.5.4 Key Developments 197
13.5.5 SWOT Analysis 197
13.5.6 Key Strategy 197
13.6 Bayer AG 198
13.6.1 Company Overview 198
13.6.2 Financial Overview 198
13.6.3 Products Offering 199
13.6.4 Key Developments 199
13.6.5 SWOT Analysis 199
13.6.6 Key Strategy 199
13.7 Pfizer Inc. 200
13.7.1 Company Overview 200
13.7.2 Financial Overview 200
13.7.3 Products Offering 201
13.7.4 Key Developments 201
13.7.5 SWOT Analysis 201
13.7.6 Key Strategy 201
13.8 Siemens AG 202
13.8.1 Company Overview 202
13.8.2 Financial Overview 202
13.8.3 Products Offering 203
13.8.4 Key Developments 203
13.8.5 SWOT Analysis 203
13.8.6 Key Strategy 203
13.9 F. Hoffmann-La Roche AG 204
13.9.1 Company Overview 204
13.9.2 Financial Overview 204
13.9.3 Products Offering 205
13.9.4 Key Developments 205
13.9.5 SWOT Analysis 205
13.9.6 Key Strategy 205
13.10 GE Healthcare 206
13.10.1 Company Overview 206
13.10.2 Financial Overview 206
13.10.3 Products Offering 207
13.10.4 Key Developments 207
13.10.5 SWOT Analysis 207
13.10.6 Key Strategy 207
13.11 Penumbra, Inc. 208
13.11.1 Company Overview 208
13.11.2 Financial Overview 208
13.11.3 Products Offering 209
13.11.4 Key Developments 209
13.11.5 SWOT Analysis 209
13.11.6 Key Strategy 210
13.12 Medtronic PLC 211
13.12.1 Company Overview 211
13.12.2 Financial Overview 211
13.12.3 Products Offering 212
13.12.4 Key Developments 212
13.12.5 SWOT Analysis 212
13.12.6 Key Strategy 213
13.13 Abbott Laboratories 214
13.13.1 Company Overview 214
13.13.2 Financial Overview 214
13.13.3 Products Offering 215
13.13.4 Key Developments 215
13.13.5 SWOT Analysis 216
13.13.6 Key Strategy 216
13.14 Merck & Co., Inc. 217
13.14.1 Company Overview 217
13.14.2 Financial Overview 217
13.14.3 Products Offering 218
13.14.4 Key Developments 218
13.14.5 SWOT Analysis 218
13.14.6 Key Strategy 218
13.15 Boehringer Ingelheim GmbH 219
13.15.1 Company Overview 219
13.15.2 Financial Overview 219
13.15.3 Products Offering 220
13.15.4 Key Developments 220
13.15.5 SWOT Analysis 220
13.15.6 Key Strategy 220
14 Conclusion
14.1 Key Findings 222
14.1.1 CEOโs Viewpoint 222
14.1.2 Unmet Needs 222
14.1.3 Key Companies To Watch 222
14.1.4 Prediction 222
15 Appendix
15.1 Discussion Blue Print 224
15.2 References 225
16 List Of Tables
TABLE 1 MARKET SYNOPSIS 24
TABLE 2 LIST OF ASSUMPTIONS 26
TABLE 3 PRIMARY INTERVIEWS 30
TABLE 4 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 50
TABLE 5 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUES, 2020โ2027 (USD MILLION) 50
TABLE 6 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY COMPUTED TOMOGRAPHY (CT) SCAN,
2020โ2027 (USD MILLION) 51
TABLE 7 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY CAROTID DUPLEX SCANNING,
2020โ2027 (USD MILLION) 51
TABLE 8 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY MAGNETIC RESONANCE IMAGING,
2020โ2027 (USD MILLION) 52
TABLE 9 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY ECHOCARDIOGRAPHY,
2020โ2027 (USD MILLION) 52
TABLE 10 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020โ2027 (USD MILLION) 55
TABLE 11 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY SURGERY, 2020โ2027 (USD MILLION) 55
TABLE 12 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 56
TABLE 13 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUG, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 56
TABLE 14 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 56
TABLE 15 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY CLOPIDOGREL, 2020โ2027 (USD MILLION) 57
TABLE 16 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY ASPIRIN, 2020โ2027 (USD MILLION) 57
TABLE 17 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 57
TABLE 18 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY ENOXAPARIN, 2020โ2027 (USD MILLION) 58
TABLE 19 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY DALTEPARIN, 2020โ2027 (USD MILLION) 58
TABLE 20 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 58
TABLE 21 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY TENECTEPLASE, 2020โ2027 (USD MILLION) 59
TABLE 22 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY ALTEPLASE 2020โ2027 (USD MILLION) 59
TABLE 23 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 59
TABLE 24 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY PRAZOSIN,
2020โ2027 (USD MILLION) 60
TABLE 25 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY MOXONIDINE,
2020โ2027 (USD MILLION) 60
TABLE 26 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUPS, 2020โ2027 (USD MILLION) 63
TABLE 27 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 0-18 YEARS, 2020โ2027 (USD MILLION) 64
TABLE 28 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 19-40 YEARS, 2020โ2027 (USD MILLION) 65
TABLE 29 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 41-60 YEARS, 2020โ2027 (USD MILLION) 65
TABLE 30 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 60+ YEARS, 2020โ2027 (USD MILLION) 65
TABLE 31 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 68
TABLE 32 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HOSPITALS, BY REGION, 2020โ2027 (USD MILLION) 69
TABLE 33 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020โ2027 (USD MILLION) 70
TABLE 34 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR RESEARCH LABORATORIES, BY REGION, 2020โ2027 (USD MILLION) 70
TABLE 35 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020โ2027 (USD MILLION) 72
TABLE 36 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020โ2027 (USD MILLION) 73
TABLE 37 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 74
TABLE 38 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 74
TABLE 39 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020โ2027 (USD MILLION) 74
TABLE 40 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 75
TABLE 41 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 75
TABLE 42 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 75
TABLE 43 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 76
TABLE 44 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 76
TABLE 45 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 76
TABLE 46 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 77
TABLE 47 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 77
TABLE 48 NORTH AMERICA: TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78
TABLE 49 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 78
TABLE 50 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
2020โ2027 (USD MILLION) 79
TABLE 51 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 79
TABLE 52 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 79
TABLE 53 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
2020โ2027 (USD MILLION) 80
TABLE 54 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 80
TABLE 55 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 80
TABLE 56 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 81
TABLE 57 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 81
TABLE 58 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 81
TABLE 59 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 82
TABLE 60 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 82
TABLE 61 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 82
TABLE 62 U.S. TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020โ2027 (USD MILLION) 83
TABLE 63 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 83
TABLE 64 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020โ2027 (USD MILLION) 83
TABLE 65 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 84
TABLE 66 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 84
TABLE 67 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 84
TABLE 68 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 85
TABLE 69 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 85
TABLE 70 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 85
TABLE 71 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 86
TABLE 72 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 86
TABLE 73 CANADA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020โ2027 (USD MILLION) 86
TABLE 74 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 87
TABLE 75 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 87
TABLE 76 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 87
TABLE 77 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 88
TABLE 78 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 88
TABLE 79 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 88
TABLE 80 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 89
TABLE 81 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 89
TABLE 82 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 90
TABLE 83 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
2020โ2027 (USD MILLION) 90
TABLE 84 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 90
TABLE 85 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 91
TABLE 86 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
2020โ2027 (USD MILLION) 91
TABLE 87 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 91
TABLE 88 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 92
TABLE 89 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 92
TABLE 90 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 92
TABLE 91 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 93
TABLE 92 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 93
TABLE 93 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020โ2027 (USD MILLION) 94
TABLE 94 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 95
TABLE 95 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 95
TABLE 96 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020โ2027 (USD MILLION) 95
TABLE 97 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 96
TABLE 98 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 96
TABLE 99 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 96
TABLE 100 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 97
TABLE 101 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 97
TABLE 102 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 97
TABLE 103 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 98
TABLE 104 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 98
TABLE 105 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 99
TABLE 106 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
2020โ2027 (USD MILLION) 99
TABLE 107 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 99
TABLE 108 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 100
TABLE 109 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
2020โ2027 (USD MILLION) 100
TABLE 110 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 100
TABLE 111 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 101
TABLE 112 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 101
TABLE 113 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 101
TABLE 114 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 102
TABLE 115 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 102
TABLE 116 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 103
TABLE 117 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 103
TABLE 118 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 103
TABLE 119 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 104
TABLE 120 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 104
TABLE 121 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 104
TABLE 122 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 105
TABLE 123 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 105
TABLE 124 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 105
TABLE 125 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 106
TABLE 126 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 106
TABLE 127 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 107
TABLE 128 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 107
TABLE 129 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 107
TABLE 130 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 108
TABLE 131 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 108
TABLE 132 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 108
TABLE 133 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 109
TABLE 134 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 109
TABLE 135 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 109
TABLE 136 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 110
TABLE 137 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 110
TABLE 138 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 111
TABLE 139 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 111
TABLE 140 U.K TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020โ2027 (USD MILLION) 111
TABLE 141 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 112
TABLE 142 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 112
TABLE 143 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020โ2027 (USD MILLION) 112
TABLE 144 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 113
TABLE 145 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020โ2027 (USD MILLION) 113
TABLE 146 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 113
TABLE 147 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 114
TABLE 148 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 114
TABLE 149 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 115
TABLE 150 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 115
TABLE 151 ITALY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 115
TABLE 152 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 116
TABLE 153 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020โ2027 (USD MILLION) 116
TABLE 154 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 116
TABLE 155 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 117
TABLE 156 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 117
TABLE 157 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 117
TABLE 158 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 118
TABLE 159 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 118
TABLE 160 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 119
TABLE 161 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 119
TABLE 162 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020โ2027 (USD MILLION) 119
TABLE 163 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 120
TABLE 164 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 120
TABLE 165 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 120
TABLE 166 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 121
TABLE 167 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 121
TABLE 168 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 121
TABLE 169 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 122
TABLE 170 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 122
TABLE 171 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 123
TABLE 172 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
2020โ2027 (USD MILLION) 123
TABLE 173 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 123
TABLE 174 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 124
TABLE 175 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
2020โ2027 (USD MILLION) 124
TABLE 176 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 124
TABLE 177 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 125
TABLE 178 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 125
TABLE 179 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 125
TABLE 180 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 126
TABLE 181 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 126
TABLE 182 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 127
TABLE 183 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
2020โ2027 (USD MILLION) 127
TABLE 184 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 127
TABLE 185 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 128
TABLE 186 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
2020โ2027 (USD MILLION) 128
TABLE 187 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 128
TABLE 188 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 129
TABLE 189 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 129
TABLE 190 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 129
TABLE 191 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 130
TABLE 192 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 130
TABLE 193 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020โ2027 (USD MILLION) 131
TABLE 194 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 132
TABLE 195 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 132
TABLE 196 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 132
TABLE 197 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 133
TABLE 198 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 133
TABLE 199 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 133
TABLE 200 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 134
TABLE 201 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 134
TABLE 202 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 134
TABLE 203 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 135
TABLE 204 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 135
TABLE 205 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 136
TABLE 206 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 136
TABLE 207 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 136
TABLE 208 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 137
TABLE 209 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 137
TABLE 210 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 137
TABLE 211 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 138
TABLE 212 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 138
TABLE 213 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 138
TABLE 214 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 139
TABLE 215 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 139
TABLE 216 CHINA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 140
TABLE 217 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 140
TABLE 218 CHINA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 140
TABLE 219 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 141
TABLE 220 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 141
TABLE 221 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 141
TABLE 222 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 142
TABLE 223 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 142
TABLE 224 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 142
TABLE 225 CHINA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 143
TABLE 226 CHINA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 143
TABLE 227 INDIA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 144
TABLE 228 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 144
TABLE 229 INDIA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 144
TABLE 230 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 145
TABLE 231 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 145
TABLE 232 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 145
TABLE 233 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020โ2027 (USD MILLION) 146
TABLE 234 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 146
TABLE 235 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 146
TABLE 236 INDIA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 147
TABLE 237 INDIA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 147
TABLE 238 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 148
TABLE 239 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 148
TABLE 240 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 148
TABLE 241 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 149
TABLE 242 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020โ2027 (USD MILLION) 149
TABLE 243 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 149
TABLE 244 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 150
TABLE 245 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 150
TABLE 246 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020โ2027 (USD MILLION) 150
TABLE 247 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 151
TABLE 248 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 151
TABLE 249 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 152
TABLE 250 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
2020โ2027 (USD MILLION) 152
TABLE 251 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 152
TABLE 252 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 153
TABLE 253 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
2020โ2027 (USD MILLION) 153
TABLE 254 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 153
TABLE 255 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 154
TABLE 256 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 154
TABLE 257 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 154
TABLE 258 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 155
TABLE 259 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 155
TABLE 260 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 156
TABLE 261 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
2020โ2027 (USD MILLION) 156
TABLE 262 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 156
TABLE 263 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 157
TABLE 264 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
2020โ2027 (USD MILLION) 157
TABLE 265 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 157
TABLE 266 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 158
TABLE 267 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 158
TABLE 268 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 158
TABLE 269 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 159
TABLE 270 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 159
TABLE 271 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020โ2027 (USD MILLION) 160
TABLE 272 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 161
TABLE 273 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
2020โ2027 (USD MILLION) 161
TABLE 274 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 161
TABLE 275 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 162
TABLE 276 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
2020โ2027 (USD MILLION) 162
TABLE 277 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 162
TABLE 278 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 163
TABLE 279 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 163
TABLE 280 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 163
TABLE 281 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 164
TABLE 282 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 164
TABLE 283 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 164
TABLE 284 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
2020โ2027 (USD MILLION) 165
TABLE 285 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 165
TABLE 286 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020โ2027 (USD MILLION) 165
TABLE 287 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
2020โ2027 (USD MILLION) 166
TABLE 288 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
2020โ2027 (USD MILLION) 166
TABLE 289 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
2020โ2027 (USD MILLION) 166
TABLE 290 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
2020โ2027 (USD MILLION) 167
TABLE 291 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
2020โ2027 (USD MILLION) 167
TABLE 292 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020โ2027 (USD MILLION) 167
TABLE 293 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020โ2027 (USD MILLION) 168
TABLE 294 SAUDI ARABIA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020โ2027 (USD MILLION) 168
TABLE 295 SAUDI ARABIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020โ2027 (USD MILLION) 168
TABLE 296 SAUDI ARABIA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020โ2027 (USD MILLION) 169
TABLE 297 SAUDI ARABIA TRANSIENT ISCHEMIC ATTACK M
17 List Of Figures
FIGURE 1 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET: MARKET STRUCTURE 27
FIGURE 2 RESEARCH PROCESS OF MRFR 29
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 32
FIGURE 4 DRIVERS & RESTRAINTS: GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET 34
FIGURE 5 PORTERS FIVE FORCES MODEL 44
FIGURE 6 SUPPLY CHAIN: TRANSIENT ISCHEMIC ATTACK MARKET 46
FIGURE 7 GLOBAL TRANSIENT ISCHEMIC ATTAK MARKET, BY DIAGNOSIS, 2020 (% SHARE) 49
FIGURE 8 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020 TO 2027 (USD MILLION) 50
FIGURE 9 GLOBAL TRANSIENT ISCHEMIC ATTAK MARKET, BY TREATMENT 2020 (% SHARE) 54
FIGURE 10 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020 TO 2027 (USD MILLION) 55
FIGURE 11 GLOBAL TRANSIENT ISCHEMIC ATTAK MARKET, BY AGE GROUP 2020 (% SHARE) 63
FIGURE 12 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUPS, 2020 TO 2027 (USD MILLION) 64
FIGURE 13 GLOBAL TRANSIENT ISCHEMIC ATTAK MARKET, BY END USER 2020 (% SHARE) 68
FIGURE 14 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020 TO 2027 (USD MILLION) 69
FIGURE 15 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020 TO 2027 (USD MILLION) 72
FIGURE 16 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020 (%) 73
FIGURE 17 NORTH AMERICA: TRANSIENT ISCHEMIC ATTACK MARKET SHARE, BY COUNTRY, 2020 (% SHARE) 78
FIGURE 18 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020 (%) 94
FIGURE 19 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020 (%) 131
FIGURE 20 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020 (%) 160
FIGURE 21 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, COMPANY SHARE ANALYSIS 2020 (%) 177
FIGURE 22 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET COMPETITIVE LANDSCAPE (%) 178